


A Systematic Literature Review of the research upon the Burden, Quality of Life and Economic Cost Impact of Glanzmann Thrombasthenia


PCR280
ISPOR EU
2024

Background: Glanzmann Thrombasthenia (GT) is a rare, inherited bleeding disorder which results in an inability to form effective clots leading to frequent bleeding events which can be potentially life-threatening and contributing to deteriorating quality of life (QoL), iron deficiency anaemia (IDA), and significant healthcare resource utilization due to lack of convenient prophylactic therapies.

Result 1: Literature Identified



Result 2: Reported Results of the Literature




Our review found that while 89% of the studies reported on bleeding burden, only 6% explored the economic costs, revealing a critical gap in understanding the broader societal impact of GT.

This lack of comprehensive data on healthcare resource utilization and productivity loss impedes the ability to advocate for better care and support services for GT patients and their families.


There is limited evidence on the burden, quality of life, and economic costs related to people with Glanzmann Thrombasthenia and their caregivers

Methods

Scope & Sources



PRISMA Flow Diagram



Conclusion: The review of these 18 studies highlights the **significant challenges** faced by individuals with GT, particularly concerning the **frequent bleed events, IDA, and their impact on QoL**. These issues are well-recognised yet often inadequately documented in existing literature. **Future research focusing on** individuals with GT and their caregivers is essential to fully characterise both the **clinical and holistic burdens of the condition**. This research should aim to **quantify the effects of bleed events and IDA on QoL**, as well as to **analyse direct healthcare costs and indirect costs** associated with productivity loss.



George Morgan¹, Amy Owen-Wyard^{2,3}, Peter Zdziarski⁴, Stacey McGeown^{2,5}, Sam Bristow¹

¹DHT.health, North West, United Kingdom; ²The Haemophilia Society, London, United Kingdom; ³The European Haemophilia Consortium, Brussels, Belgium; ⁴Glanzmann Research Foundation Inc, Georgia, USA; ⁵Queen's University, Belfast, United Kingdom

DHT.health
VALUE THROUGH EVIDENCE

We would like to thank Hemab ApS for funding this publication.